Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination

Servier Hellas Pharmaceuticals Ltd.2,285 enrolled

Overview

The main objective of this study is to record, in routine clinical practice, patients' adherence to treatment with Perindopril/Indapamide/Amlodipine fixed dose combination, during 4 months treatment.

This is a non-interventional study aiming to record adherence to treatment with Perindopril/Indapamide/Amlodipine fixed dose combination. In parallel blood pressure levels will be recorded, as well as safety and tolerability of this fixed dose combination.

Study Type

OBSERVATIONAL

Enrollment

2,285

Conditions

Adherence to Medication Regime Hypertensive Disease

Interventions

Perindopril/Indapamide/Amlodipine fixed dose combinationDRUG

Dose selection is based on investigators management.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, ambulatory patients \>18 years old. * Clinically diagnosed essential arterial hypertension. * Under treatment with Perindoril/Indapamide/Amlodipine fixed dose combination. * The patient has given his/her written consent after being informed, before his inclusion in the study. Exclusion Criteria: * Secondary arterial hypertension. * Serious end stage diseases, severe neuropsychiatric diseases, cerebrovascular event with serious residual lesions, scheduled procedure or surgical operation or hospital admission. * Pregnancy, lactation or intention to become pregnant.

Locations (1)

Ippokratio University Hospital of Athens

Athens, Greece

Outcomes

Primary Outcomes

Adherence to treatment

Total score of Hill-Bone High Blood Pressure Compliance Scale will be recorded at each study visit

Time frame: Change of total score of compliance scale between baseline and 1st month and between 1st and 4th month of treatment

Secondary Outcomes

Systolic Blood Pressure

Time frame: All visits (baseline, 1st and 4th month of treatment)

Diastolic Blood Pressure

Time frame: All visits (baseline, 1st and 4th month of treatment)

Adverse events recording leading to treatment discontinuation

Time frame: 1st and 4th month of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.